Phase III Study of NT-501 (CNTF implant) in Macular Telangiectasia Type 2
Macular Telangiectasia Type 2 (MacTel)
Enrolment: 120 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Macular Telangiectasia Type 2 (MacTel)
Enrolment: 120 · Results not recorded
Macular Telangiectasia Type 2
Enrolment: 119 · Results not recorded
Macular Telangiectasia Type 2
Enrolment: 12 · Results not recorded
Retinitis Pigmentosa
Enrolment: 67 · Results not recorded
Retinitis Pigmentosa · Usher Syndrome Type 2 · Usher Syndrome Type 3
Enrolment: 22 · Results not recorded
MacTel (Macular Telangiectasia) Type 2
Enrolment: 70 · Results not recorded
Nonexudative Age-Related Macular Degeneration, Intermediate Dry Stage
Enrolment: 53 · Results not recorded
Retinitis Pigmentosa
Enrolment: 73 · Results not recorded
Idiopathic Juxtafoveal Telangiectasia
Enrolment: 7 · Results not recorded
Retinitis Pigmentosa
Enrolment: 10 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Intraorbital optic nerve crush with jeweller's forceps (Dumont no. 5) for 10 seconds approximately 1 mm behind the optic disc
AAV-CNTF delivered 56 days after crush produced regenerating axons beyond 1 mm in 5 of 5 mice versus none with AAV-GFP, with fewer misguided axons than acute treatment (2.7 +/- 2.3 per cent versus 14.7 +/- 2.1 per cent, P = 0.0029), despite retinal ganglion cell survival falling to 4.0 +/- 0.3 per…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.